Abstract
Experimental studies and early-phase clinical trials suggest that mobilization of bone marrow stem cells by granulocyte-colony-stimulating factor (G-CSF) can be used to improve cardiac regeneration after acute myocardial infarction (AMI). In order to more fully evaluate this intervention in patients with AMI, we conducted the Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells (REVIVAL-2) clinical trial. Following successful reperfusion by percutaneous coronary intervention for AMI, patients were randomly assigned to receive a subcutaneous daily dose of 10 µg/kg G-CSF or placebo for 5 days. Treatment with G-CSF produced a significant mobilization of stem cells. After 4–6 months the reduction in infarct size from baseline, as determined by technetium-99-labeled single-photon-emission CT, did not differ significantly between the G-CSF group and the placebo group. Furthermore, the improvement in left ventricular ejection fraction, as assessed by late-enhancement MRI, did not differ significantly between the two groups. G-CSF treatment did not increase the risk of adverse clinical events and did not promote restenosis. Our trial demonstrates that stem cell mobilization by G-CSF does not improve infarct size, left ventricular function, or coronary restenosis in patients with AMI who have had successful mechanical reperfusion.
Key Points
-
G-CSF therapy is safe and feasible in patients with acute myocardial infarction
-
G-CSF treatment does not increase the risk of restenosis
-
No improvement in left ventricular recovery is seen in patients with acute myocardial infarction treated with mechanical reperfusion after G-CSF therapy
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zohlnhofer D et al. (2006) Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 295: 1003–1010
Dimmeler S et al. (2005) Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest 115: 572–583
Forrester JS et al. (2003) Stem cell repair of infarcted myocardium: an overview for clinicians. Circulation 108: 1139–1145
Fox KF et al. (2001) Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 22: 228–236
Levy D et al. (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347: 1397–1402
Roger VL et al. (2004) Trends in heart failure incidence and survival in a community-based population. JAMA 292: 344–350
Orlic D et al. (2001) Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 98: 10344–10349
Maekawa Y et al. (2004) Effect of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 44: 1510–1520
Kawamoto A et al. (2004) Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia. Circulation 110: 1398–1405
Wojakowski W et al. (2004) Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 110: 3213–3220
Kang HJ et al. (2004) Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 363: 751–756
Valgimigli M et al. (2005) Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur Heart J 26: 1838–1845
Ince H et al. (2005) Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 112: 3097–3106
Sesti C et al. (2005) Granulocyte colony-stimulating factor and stem cell factor improve contractile reserve of the infarcted left ventricle independent of restoring muscle mass. J Am Coll Cardiol 46: 1662–1669
Kocher AA et al. (2001) Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7: 430–436
Minatoguchi S et al. (2004) Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 109: 2572–2580
Harada M et al. (2005) G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 11: 305–311
Ripa RS et al. (2006) Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 113: 1983–1992
Lapidot T et al. (2005) How do stem cells find their way home? Blood 106: 1901–1910
Shintani S et al. (2001) Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103: 2776–2779
Schömig K et al. (2006) Interleukin-8 is associated with circulating CD133+ progenitor cells in acute myocardial infarction. Eur Heart J 27: 1032–1037
Schachinger V et al.; REPAIR-AMI Investigators (2006) Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355: 1210–1221
Carion A et al. (2002) Decreased stroma adhesion capacity of CD34+ progenitor cells from mobilized peripheral blood is not lineage- or stage-specific and is associated with low beta 1 and beta 2 integrin expression. J Hematother Stem Cell Res 11: 491–500
Dlubek D et al. (2006) Low CXCR4 membrane expression on CD34(+) cells characterizes cells mobilized to blood. Bone Marrow Transplant 37: 19–23
Molineux G et al. (1990) A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. Blood 75: 563–569
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Zohlnhöfer, D., Kastrati, A. & Schömig, A. Stem cell mobilization by granulocyte-colony-stimulating factor in acute myocardial infarction: lessons from the REVIVAL-2 trial. Nat Rev Cardiol 4 (Suppl 1), S106–S109 (2007). https://doi.org/10.1038/ncpcardio0745
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0745
This article is cited by
-
Catheter-based Intramyocardial Injection of FGF1 or NRG1-loaded MPs Improves Cardiac Function in a Preclinical Model of Ischemia-Reperfusion
Scientific Reports (2016)
-
Altered myocardial glucose utilization and the reverse mismatch pattern on rubidium-82 perfusion/F-18-FDG PET during the sub-acute phase following reperfusion of acute anterior myocardial infarction
Journal of Nuclear Cardiology (2011)
-
Endothelial progenitor cells and their potential clinical implication in cardiovascular disorders
Journal of Endocrinological Investigation (2009)
-
Cell vehicle targeting strategies
Gene Therapy (2008)